- Sweden
- /
- Medical Equipment
- /
- OM:ARJO B
Arjo Second Quarter 2025 Earnings: EPS: kr0.34 (vs kr0.44 in 2Q 2024)
Arjo (STO:ARJO B) Second Quarter 2025 Results
Key Financial Results
- Revenue: kr2.68b (down 4.7% from 2Q 2024).
- Net income: kr92.0m (down 23% from 2Q 2024).
- Profit margin: 3.4% (down from 4.3% in 2Q 2024).
- EPS: kr0.34 (down from kr0.44 in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Arjo Earnings Insights
Looking ahead, revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in Sweden.
Performance of the Swedish Medical Equipment industry.
The company's shares are down 2.1% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Arjo has 3 warning signs we think you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:ARJO B
Arjo
Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia, Latin America, Africa, and the Pacific.
Very undervalued with excellent balance sheet.
Similar Companies
Market Insights
Weekly Picks

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

Adobe: A Probabilistic Case for Undervaluation

A Capital Allocation Favorite with Structural Importance

Good foundation, but now it's all about the next steps
Recently Updated Narratives

An Overlooked AI Play That’s Quietly Building a Healthcare Data Empire
Undervalued, Underestimated
Tanco's Pullback Brings Key Accumulation Zones Into Focus
Popular Narratives

Investment Analysis (May 2026)

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Honeywell - The Demand-Side of the AI Infrastructure
Trending Discussion
It's wonderful. It has greatly helped me take informed decisions.

